| pubmed-article:17903213 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17903213 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:17903213 | lifeskim:mentions | umls-concept:C0026764 | lld:lifeskim |
| pubmed-article:17903213 | lifeskim:mentions | umls-concept:C0001271 | lld:lifeskim |
| pubmed-article:17903213 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:17903213 | lifeskim:mentions | umls-concept:C1511695 | lld:lifeskim |
| pubmed-article:17903213 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:17903213 | lifeskim:mentions | umls-concept:C0392938 | lld:lifeskim |
| pubmed-article:17903213 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:17903213 | pubmed:dateCreated | 2007-10-10 | lld:pubmed |
| pubmed-article:17903213 | pubmed:abstractText | New strategies are needed to overcome the resistance of multiple myeloma (MM) to dexamethasone (Dex). Several recent in vitro studies demonstrated the antitumor effect of nitrogen-containing amino-bisphosphonates (N-BPs) in various tumor cell lines. Inhibition of the prenylation of small G proteins is assumed to be one of the principal mechanisms by which N-BPs exert their effects. There have been few reports on N-BP treatment of MM cells that are resistant to Dex. Additionally, it is not known how small G proteins are altered in N-BP-treated MM cells. In this study, we evaluated the effect of the most potent N-BP, zoledronate (ZOL), on a Dex-resistant human MM cell subline (Dex-R) that we established from the well-documented RPMI8226 cell line. ZOL reduced the viability and induced apoptosis of Dex-R cells. Some of the ZOL-treated RPMI8226 cells and ZOL-treated Dex-R cells were elongated; however, elongated cells were not seen among the Dex-treated RPMI8226 cells. Furthermore, we found that portions of the small G proteins, Rho and Rap1A, were unprenylated in the ZOL-treated MM cells. Geranylgeraniol reduced the above-mentioned ZOL-induced effects. These findings suggest that ZOL may be beneficial for the treatment of Dex-resistant MM by suppressing the processing of RhoA and Rap1A. | lld:pubmed |
| pubmed-article:17903213 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17903213 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17903213 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17903213 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17903213 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17903213 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17903213 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17903213 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17903213 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17903213 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17903213 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17903213 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17903213 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17903213 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17903213 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17903213 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17903213 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17903213 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:17903213 | pubmed:issn | 0902-4441 | lld:pubmed |
| pubmed-article:17903213 | pubmed:author | pubmed-author:SaitoYasushiY | lld:pubmed |
| pubmed-article:17903213 | pubmed:author | pubmed-author:TakeuchiMasah... | lld:pubmed |
| pubmed-article:17903213 | pubmed:author | pubmed-author:ShimizuNaomiN | lld:pubmed |
| pubmed-article:17903213 | pubmed:author | pubmed-author:NishimuraMiki... | lld:pubmed |
| pubmed-article:17903213 | pubmed:author | pubmed-author:NakasekoChiak... | lld:pubmed |
| pubmed-article:17903213 | pubmed:author | pubmed-author:KoizumiMasayu... | lld:pubmed |
| pubmed-article:17903213 | pubmed:author | pubmed-author:ChoRyukoR | lld:pubmed |
| pubmed-article:17903213 | pubmed:author | pubmed-author:OzawaShinichi... | lld:pubmed |
| pubmed-article:17903213 | pubmed:author | pubmed-author:OhwadaChikako... | lld:pubmed |
| pubmed-article:17903213 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17903213 | pubmed:volume | 79 | lld:pubmed |
| pubmed-article:17903213 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17903213 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17903213 | pubmed:pagination | 382-91 | lld:pubmed |
| pubmed-article:17903213 | pubmed:dateRevised | 2008-7-29 | lld:pubmed |
| pubmed-article:17903213 | pubmed:meshHeading | pubmed-meshheading:17903213... | lld:pubmed |
| pubmed-article:17903213 | pubmed:meshHeading | pubmed-meshheading:17903213... | lld:pubmed |
| pubmed-article:17903213 | pubmed:meshHeading | pubmed-meshheading:17903213... | lld:pubmed |
| pubmed-article:17903213 | pubmed:meshHeading | pubmed-meshheading:17903213... | lld:pubmed |
| pubmed-article:17903213 | pubmed:meshHeading | pubmed-meshheading:17903213... | lld:pubmed |
| pubmed-article:17903213 | pubmed:meshHeading | pubmed-meshheading:17903213... | lld:pubmed |
| pubmed-article:17903213 | pubmed:meshHeading | pubmed-meshheading:17903213... | lld:pubmed |
| pubmed-article:17903213 | pubmed:meshHeading | pubmed-meshheading:17903213... | lld:pubmed |
| pubmed-article:17903213 | pubmed:meshHeading | pubmed-meshheading:17903213... | lld:pubmed |
| pubmed-article:17903213 | pubmed:meshHeading | pubmed-meshheading:17903213... | lld:pubmed |
| pubmed-article:17903213 | pubmed:meshHeading | pubmed-meshheading:17903213... | lld:pubmed |
| pubmed-article:17903213 | pubmed:meshHeading | pubmed-meshheading:17903213... | lld:pubmed |
| pubmed-article:17903213 | pubmed:meshHeading | pubmed-meshheading:17903213... | lld:pubmed |
| pubmed-article:17903213 | pubmed:meshHeading | pubmed-meshheading:17903213... | lld:pubmed |
| pubmed-article:17903213 | pubmed:meshHeading | pubmed-meshheading:17903213... | lld:pubmed |
| pubmed-article:17903213 | pubmed:meshHeading | pubmed-meshheading:17903213... | lld:pubmed |
| pubmed-article:17903213 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17903213 | pubmed:articleTitle | Zoledronate has an antitumor effect and induces actin rearrangement in dexamethasone-resistant myeloma cells. | lld:pubmed |
| pubmed-article:17903213 | pubmed:affiliation | Division of Hematology, Department of Clinical Cell Biology, Chiba University Graduate School of Medicine, Inohana, Chuo-ku, Chiba City, Chiba, Japan. | lld:pubmed |
| pubmed-article:17903213 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17903213 | lld:pubmed |
